Boston Scientific Corp. (BSX) — 分析摘要
Boston Scientific Corp.（BSX）的市值为67.88十亿美元，最近一年的营收同比增长了+19.9%。净利润率为14.4%。当前市盈率为18.5倍。
核心要点
- 营收同比变化+19.9%
- 净利润率14.4%
- 市盈率18.5倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，BSX的营收增长为+19.9%，市盈率为18.5倍。
Boston Scientific Corp. (BSX)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
59,000
总部
MARLBOROUGH, MA
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。